000132105 001__ 132105
000132105 005__ 20250129092404.0
000132105 037__ $$aFZJ-2013-01344
000132105 1001_ $$0P:(DE-HGF)0$$aSabri, O (Corresponding author)$$b0$$eCorresponding author
000132105 1112_ $$aAnnual Congress of the European Association of Nuclear Medicine$$cMilan$$d2012-10-27 - 2012-10-31$$gEANM2012$$wItaly
000132105 245__ $$aCerebral Nicotinic Acetylcholine Receptors (nAChRs) In EarlyAlzheimer’s Disease (AD) Assessed With The New Radioligand [18F]Flubatine and PET
000132105 260__ $$c2012
000132105 3367_ $$0PUB:(DE-HGF)6$$2PUB:(DE-HGF)$$aConference Presentation$$bconf$$mconf$$s1361373979_4831$$xOther
000132105 3367_ $$033$$2EndNote$$aConference Paper
000132105 3367_ $$2DataCite$$aOther
000132105 3367_ $$2ORCID$$aLECTURE_SPEECH
000132105 3367_ $$2DRIVER$$aconferenceObject
000132105 3367_ $$2BibTeX$$aINPROCEEDINGS
000132105 520__ $$aObjectives: There is evidence from post‐mortem studies that the loss of nAChRs, in particular of the alpha4beta2‐nAChR, which is obviously most severely reduced at the onset of AD, is a major contributor to the cognitive deterioration in AD. Accordingly, using 2‐[18F]F‐A85380 PET we showed significant declines in alpha4beta2‐nAChRs in early AD‐patients (Sabri et al. 2008; Kendziorra et al. 2010). However, this tracer was not well suited as a biomarker in a routine clinical set‐up for early AD‐diagnosis because of unfavourable properties (especially long acquisition times up to 7 hours). We, therefore, developed the new radiotracer (‐)‐ [18F]NCFHEB (denominated as [18F]Flubatine) with significantly improved brain uptake and also better nAChR affinity and selectivity (Brust et al. 2008). Here, we present the results of the worldwide first ongoing [18F]Flubatine‐PET study in humans. Methods: 19 mild AD‐patients (NINCDS‐ADRDA, age 74.5±6.2, MMSE 23.7±2.7) and 20 age‐matched healthy controls (HC, age 70.6±4.6, MMSE 28.5±0.8) underwent [18F]Flubatine‐PET (370 MBq, 3D‐acquisition, ECAT Exact HR+, 4 scans, 0‐270 min p.i., motion correction with SPM2). All were nonsmokers and naïve for central acting medication. Kinetic modeling was applied to the VOI‐based tissueactivity curves generated for 29 brain regions. Total distribution volume (DV) and binding potential (BP, reference region: corpus callosum) were used to characterize specific binding. Additionally, parametric images of DV were computed (Logan plot). Results: Image quality of [18F]Flubatine scans was clearly superior to 2‐[18F]FA85380, and a 20 minutes scan already adequate for visual analysis. PET data acquired over only 90 minutes were sufficient to estimate all kinetic parameters of all VOIs with 1‐tissue compartment model. Thirty‐minute scans were already sufficient for modelling of all cortical VOIs. Tracer distribution was similar to known alpha4beta2‐nAChR distribution and DVs in HCs increase as expected with receptor density with the lowest DV in the corpus callosum (5.64±0,87) and highest in the thalamus (24.67±3.91). The AD‐patients showed significant BP reductions in distinct cortical regions (p<0.05) compared to HCs. Conclusions: Due to significant faster kinetics and shorter acquisition time enabling full kinetic modeling within 90 minutes, and superior image quality [18F]Flubatine appears to be a much more suitable tracer than 2‐[18F]F‐A85380 to image alpha4beta2‐nAChRs in humans. In keeping with its diagnostic properties, early AD‐patients show declines of alpha4beta2‐nAChRs in distinct cortical regions typically affected by AD‐pathology. These results indicate that [18F]Flubatine‐PET could have a great potential to be tested as a biomarker for early AD‐diagnosis.
000132105 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000132105 536__ $$0G:(DE-Juel1)BMBF-01EZ0822$$aBMBF-01EZ0822 - NorChloro-Fluoro HomoEpiBatidin (NCFHEB)  ein potentieller Positronen-Emission Tomographie-(PET) Marker der frühen Alzheimer-Demenz (BMBF-01EZ0822)$$cBMBF-01EZ0822$$x1
000132105 7001_ $$0P:(DE-HGF)0$$aWilke, S$$b1
000132105 7001_ $$0P:(DE-HGF)0$$aGraef, S$$b2
000132105 7001_ $$0P:(DE-HGF)0$$aLengler, U$$b3
000132105 7001_ $$0P:(DE-HGF)0$$aSchoenknecht, P$$b4
000132105 7001_ $$0P:(DE-HGF)0$$aGertz, H$$b5
000132105 7001_ $$0P:(DE-HGF)0$$aBecker, G$$b6
000132105 7001_ $$0P:(DE-HGF)0$$aLuthardt, J$$b7
000132105 7001_ $$0P:(DE-HGF)0$$aPatt, M$$b8
000132105 7001_ $$0P:(DE-HGF)0$$aHesse, S$$b9
000132105 7001_ $$0P:(DE-HGF)0$$aBarthel, H$$b10
000132105 7001_ $$0P:(DE-Juel1)133954$$aWagenknecht, Gudrun$$b11
000132105 7001_ $$0P:(DE-HGF)0$$aHoepping, A$$b12
000132105 7001_ $$0P:(DE-HGF)0$$aHegerl, U$$b13
000132105 7001_ $$0P:(DE-HGF)0$$aBrust, P$$b14
000132105 909CO $$ooai:juser.fz-juelich.de:132105$$pVDB
000132105 9101_ $$0I:(DE-Juel1)ZEA-2-20090406$$6P:(DE-Juel1)133954$$aZentralinstitut für Elektronik$$b11$$kZEA-2
000132105 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133954$$aForschungszentrum Jülich GmbH$$b11$$kFZJ
000132105 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000132105 9141_ $$y2012
000132105 9201_ $$0I:(DE-Juel1)ZEL-20090406$$kZEL$$lZentralinstitut für Elektronik$$x0
000132105 9201_ $$0I:(DE-Juel1)ZEA-2-20090406$$kZEA-2$$lZentralinstitut für Elektronik$$x1
000132105 980__ $$aconf
000132105 980__ $$aVDB
000132105 980__ $$aUNRESTRICTED
000132105 980__ $$aI:(DE-Juel1)ZEL-20090406
000132105 980__ $$aI:(DE-Juel1)ZEA-2-20090406
000132105 981__ $$aI:(DE-Juel1)PGI-4-20110106
000132105 981__ $$aI:(DE-Juel1)ZEA-2-20090406